Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran Etexilate for Prevention of Recurrent VTE
NCT00558259Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2007
- Primary completion
- Feb 2011
- Modality
- Small Molecules
- Countries
- 21
01
Overview
A Phase 3 trial of dabigatran in venous thromboembolism (VTE), sponsored by Boehringer Ingelheim. Started Nov 2007; status: completed.
02
Drugs
dabigatran
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00558259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00558259.